Myocardial bradykinin B2-receptor expression at different time points after induction of myocardial infarction

Journal of Hypertension

Volumn 18, Issue 2, 2000, Pages 223-228

  Tschöpe, Carsten ^b   Heringer Walther, Silvia ^c   Koch, Matthias ^c   Spillmann, Frank ^c   Wendorf, Michael ^c   Hauke, Dorian ^c   Bader, Michael ^a   Schultheiss, Heinz P ^c   Walther, Thomas ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c NONE

Author keywords

B2 receptor; Bradykinin; Kallikrein kinin system; Myocardial infarction

Indexed keywords

BRADYKININ B2 RECEPTOR; PROTEIN; RNA; BRADYKININ RECEPTOR; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY OCCLUSION; ARTICLE; CONTROLLED STUDY; HEART INFARCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE PRESSURE; HEART RIGHT VENTRICLE; HEART VENTRICLE CONTRACTILITY; HEART VENTRICLE SEPTUM; IMMUNOBLOTTING; LEFT CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; GENETICS; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; KALLIKREIN KININ SYSTEM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME; UPREGULATION;

ANIMALS; KALLIKREIN-KININ SYSTEM; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, BRADYKININ B2; RECEPTORS, BRADYKININ; RNA, MESSENGER; TIME FACTORS; UP-REGULATION; VENTRICULAR FUNCTION, LEFT;

EID: 0034134014     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200018020-00014     Document Type: Article

References (30)

1. 1 Tschöpe C, Gohlke P, Zhu Y-Z, Linz W, Schölkens BA, Unger T. Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: role of kinins. J Card Fail 1997; 3:134-148.
2. 2 Pitt B, Mason J, Conti CR, Colman RW. Activation of the plasma kallikrein system during myocardial ischemia. Adv Exp Med Biol 1970; 8:343-347.
3. 3 Kimura E, Hashimoto K, Furakawa H. Changes in bradykinin level in coronary sinus blood after the experimental occlusion a coronary artery. Am Heart J 1973; 85:635-647.
4. 4 Hashimoto K, Hirose M, Furukawa K, Hayakawa H, Kimura E. Changes in hemodynamic and bradykinin concentration in coronary sinus blood in experimental coronary artery occlusion. Jpn Heart J 1977; 18:679-680.
5. 5 Marshall RJ, Parratt JR. The early consequences of myocardial ischemia and their modification. J Physiol 1980; 976:699-715.
6. 6 Baumgarten CR, Linz W, Kunkel G, Schölkens BA, Wiemer G. Ramiprilat increases bradykinin outflow from isolated rat hearts. Br J Pharmacol 1993; 108:293-295.
7. 7 Lamontagne D, Nadeau R, Adam A. Effect of enalaprilat on bradykinin and des-Arg9-bradykinin release following reperfusion of the ischemic rat heart. Br J Pharmacol 1995; 115:476-478.
8. 8 Hashimoto K, Hamamoto H, Honda Y, Hirose M, Furukawa S, Kimura E. Changes in components of kinin system and hemodynamic in acute myocardial infarction. Am Heart J 1978; 95:619-626.
9. 9 Scicli AG, Mindrooiu T, Scicli G, Carretero OA. Blood kinins, their concentrations in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. J Lab Clin Med 1982; 100:81-93.
10. 10 Shimamoto K, Ando T, Tanaka S, Nakahashi Y, Nishitani T, Hosoda S, et al. An improved method for the determination of human blood kinin levels by sensitive kinin radioimmunoassay. Endocrinol Jpn 1982; 29:487-494.
11. 11 Nolly H, Carbini LA, Scicli G, Carretero OA, Scicli, AG. A local kallikreinkinin system is present in hearts. Hypertension 1994; 23:919-923.
12. 12 Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44:1-80.
13. 13 Weber KT, Sun Y, Katwa LC, Cleutjens JPM. Connective tissue: a metabolic entity? J Mol Cell Cardiol 1995; 27:107-120.
14. 14 Tschöpe C, Koch M, Spillmann F, Heringer-Walther S, Mochmann H-C, Stauss H, et al. Upregulation of cardiac bradykinin B2 receptors after myocardial infarction. Immunopharmacology, 1999; 44:111-117.
15. 15 Faussner A, Heinz-Erian P, Klier C, Roscher AA. Solubilization and characterization of B2 bradykinin receptors from cultured human fibroblasts. J Biol Chem 1991; 266:9442-9946.
16. 16 AbdAlla S, Buschko J, Quitterer U, Maidhof A, Haasemann M, Breipohl G, et al. Structural features of the human bradykinin B2 receptor probed by agonists, antagonists, and anti-idiotypic antibodies. J Biol Chem 1993; 268:17277-17285.
17. 17 Blaukat A, AbdAlla S, Lohse MJ, Müller-Esterl W. Ligand-induced phosphorylation/dephosphorylation of the endogenous bradykinin B2 receptor from human fibroblasts. J Biol Chem 1996; 271:32366-32374.
18. 18 Tschöpe C, Walther T, Yu M-H, Koch M, Seligmann Ch, Heringer-Walther S, et al. Myocardial expression of rat bradykinin receptors and two tissue kallikrein genes in experimental diabetes. Immunopharmacology 1999, 44:35-42.
19. 19 Parratt JR. Endogenous myocardial protective (antiarrhythmic) substances. Cardiovasc Res 1993; 27:693-702.
20. 20 Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47:25-49.
21. 21 Minshall RD, Nakamura F, Becker RP, Rabito SF. Characterisation of bradykinin B2 receptors in adult myocardium and neonatal rat cardiomyocytes. Circ Res 1995; 76:773-780.
22. 22 Praddaude F, Tack I, Emond C, Bascands JL, Girolami JP, Tran-Van T, et al. In vivo and in vitro homologous desentization of rat glomerular bradykinin B2 receptors. Eur J Pharmacol 1995; 294:173-182.
23. 23 Tiffany CW, Burch RM. Bradykinin stimulates tumor necroses factor and interleukin 1β release from macrophages. FEBS Lett 1989; 247:189-192.
24. 24 Pan ZK, Zuraw BL, Lung C-C, Prossnitz ER, Browning DD, Ye RD. Bradykinin stimulates NF-κB activation and interleukin 1β gene expression in cultured human fibroblasts. J Clin Invest 1996; 98:2042-2049.
25. 25 Sun Y, Diaz-Arias AA, Weber KT. Angiotensin-converting enzyme, bradykinin and angiotensin II receptor binding in rat skin, tendon and heart valves: an in vitro quantitative autoradiographic study. J Lab Clin Med 1994; 123:372-377.
26. 26 Kim NN, Villegas S, Summerour SR, Villarreal FJ. Regulation of cardiac fibroblast extracellular matrix production by bradykinin and nitric oxide. J Mol Cell Cardiol 1999; 31:457-466.
27. 27 Martorana PA, Kettenbach B, Breipohl G, Linz W, Schölkens BA. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 1990; 182:395-396.
28. 28 Stauss HM, Zhu YC, Redlich T, Adamiak D, Mott A, Kregel K, Unger T. ACE inhibitors in infarct induced heart failure: bradykinin versus angiotensin II. J Cardiovasc Risk 1994; 1:255-262.
29. 29 McDonald KM, Carlyle PF, Mathews J, Hauer K, Elbers T, Hunter D, et al. Early ventricular remodelling after myocardial damage and its attenuation by converting enzyme inhibition. Trans Assoc Am Physicians 1990; 103:229-235.
30. 30 Hu K, Goudron P, Anders H-J, Weidemann F, Turschner O, Nahrendorf M, Ertl G. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. Cardiovasc Res 1998; 39:401-412.